CT自动测量肝脾体积比预测HBV代偿性肝硬化失代偿
本研究用深度学习算法在1027例HBV代偿性肝硬化患者CT上自动测量肝脾体积比(LSVR),发现LSVR是肝失代偿和无移植生存的独立预测因子;LSVR<2.9者3年肝失代偿和肝相关死亡/移植风险显著高于LSVR≥2.9者。
要点
- LSVR<2.9提示HBV代偿性肝硬化患者肝失代偿和肝相关死亡/移植风险显著增高。
- LSVR经深度学习自动测量,可作为CT阅片时的预后指标。
- LSVR的预后价值独立于Child-Pugh和MELD评分。
核心结论
- CT测量的LSVR可预测HBV代偿性肝硬化患者的肝失代偿和无移植生存。
- LSVR<2.9者3年肝失代偿风险为16.7%,显著高于LSVR≥2.9者的2.5%。
- LSVR<2.9者3年肝相关死亡或移植风险为10.0%,显著高于LSVR≥2.9者的1.1%。
研究设计与样本
- 回顾性队列研究,纳入2007-2010年连续1027例HBV代偿性肝硬化患者,平均年龄50.5岁,男675例、女352例。
- 采用深度学习算法在肝脏CT图像上自动测量LSVR。
- 采用多因素Cox比例风险模型和竞争风险分析,校正Child-Pugh评分或MELD评分及其他变量。
- 采用Kaplan-Meier分析和Aalen-Johansen估计器评估肝相关事件风险。
诊断标准与关键数值
- LSVR<2.9为高风险阈值,对应3年肝失代偿风险16.7%、肝相关死亡或移植风险10.0%。
- LSVR≥2.9对应3年肝失代偿风险2.5%、肝相关死亡或移植风险1.1%。
- 校正Child-Pugh评分模型后,LSVR每增加1,肝失代偿风险比0.71(p<0.001),无移植生存风险比0.8(p<0.001)。
- 校正MELD评分模型后,LSVR每增加1,肝失代偿风险比0.68(p<0.001),无移植生存风险比0.77(p<0.001)。
- 按Child-Pugh A vs B-C和MELD<10 vs ≥10分层后,LSVR<2.9仍与更高肝相关事件风险相关(Child-Pugh p≤0.045,MELD p≤0.009)。
临床应用与阅片要点
- 在HBV代偿性肝硬化患者腹部CT报告中可提及自动测量的LSVR,LSVR<2.9提示预后不良。
- LSVR可作为Child-Pugh和MELD评分之外的补充预后指标。
局限性
- 原文未明确报告研究局限性。
- 研究为单中心回顾性队列,证据等级受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: Although the liver-to-spleen volume ratio (LSVR) based on CT reflects portal hypertension, its prognostic role in cirrhotic patients has not been proven. We evaluated the utility of LSVR, automatically measured from CT images using a deep learning algorithm, as a predictor of hepatic decompensation and transplantation-free survival in patients with hepatitis B viral (HBV)-compensated cirrhosis.
MATERIALS AND METHODS: A deep learning algorithm was used to measure the LSVR in a cohort of 1027 consecutive patients (mean age, 50.5 years; 675 male and 352 female) with HBV-compensated cirrhosis who underwent liver CT (2007-2010). Associations of LSVR with hepatic decompensation and transplantation-free survival were evaluated using multivariable Cox proportional hazards and competing risk analyses, accounting for either the Child-Pugh score (CPS) or Model for End Stage Liver Disease (MELD) score and other variables. The risk of the liver-related events was estimated using Kaplan-Meier analysis and the Aalen-Johansen estimator.
RESULTS: After adjustment for either CPS or MELD and other variables, LSVR was identified as a significant independent predictor of hepatic decompensation (hazard ratio for LSVR increase by 1, 0.71 and 0.68 for CPS and MELD models, respectively; p < 0.001) and transplantation-free survival (hazard ratio for LSVR increase by 1, 0.8 and 0.77, respectively; p < 0.001). Patients with an LSVR of < 2.9 (n = 381) had significantly higher 3-year risks of hepatic decompensation (16.7% vs. 2.5%, p < 0.001) and liver-related death or transplantation (10.0% vs. 1.1%, p < 0.001) than those with an LSVR ≥ 2.9 (n = 646). When patients were stratified according to CPS (Child-Pugh A vs. B-C) and MELD (< 10 vs. ≥ 10), an LSVR of < 2.9 was still associated with a higher risk of liver-related events than an LSVR of ≥ 2.9 for all Child-Pugh (p ≤ 0.045) and MELD (p ≤ 0.009) stratifications.
CONCLUSION: The LSVR measured on CT can predict hepatic decompensation and transplantation-free survival in patients with HBV-compensated cirrhosis.
引用
- Kwon JH, Lee SS, Yoon JS, et al. Liver-to-Spleen Volume Ratio Automatically Measured on CT Predicts Decompensation in Patients with B Viral Compensated Cirrhosis. Korean J Radiol. 2021. PMID: 34564961. doi:10.3348/kjr.2021.0348
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。